10-K · March 2, 2026
Amarin remains a single-product commercial pharmaceutical company centered on VASCEPA/VAZKEPA; Q4 2025 revenue was $49,219,000 with GAAP EPS of $0.01, while management is pursuing cost reduction and partnership-led…
Earnings analysis · 10-Q
AMRN earnings analysis
Filed April 29, 2026 · Our reading of the company's report
The latest report
Amarin Corporation's Q1 2026 report revealed a strong performance with revenues of $45.1 million, surpassing estimates, and a notable improvement in diluted EPS at -$0.03, significantly beating the expected -$0.41.…
Read full summary
Amarin Corporation's Q1 2026 report revealed a strong performance with revenues of $45.1 million, surpassing estimates, and a notable improvement in diluted EPS at -$0.03, significantly beating the expected -$0.41. Management remains optimistic about achieving positive cash flow for the full year 2026, aided by recent cost optimization initiatives, despite facing ongoing competition and restructuring costs.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.03
What stood out
-
Revenue Exceeds Expectations
Q1 2026 revenues were $45.1 million, beating the consensus of $43.4 million.
-
Significant EPS Improvement
Diluted EPS was -$0.03, much better than the expected -$0.41.
-
Cost Optimization Progress
Management highlighted successful initial steps in cost optimization that support revenue growth.
-
Confidence in Positive Cash Flow
Amarin reaffirms expectations for positive cash flow throughout 2026.
-
Inventory Management
Inventory stood at $183.6 million, ensuring supply chain stability.
-
R&D Emphasis on VASCEPA
Continued investment in research supports future growth in cardiovascular therapeutics.
What to watch
-
Restructuring Costs
Ongoing restructuring could lead to additional expenses impacting short-term margins.
-
Generic Competition
Increased competition from approved generics for VASCEPA may erode market share.
-
European Revenue Decline
Continued softness in European sales could negatively affect overall performance.
Management's outlook
Management anticipates maintaining positive cash flow throughout 2026.
Earlier filings 4
10-Q · May 7, 2025
Amarin reported Q1 revenue of $42.0M, down $14.5M (-25.7%) versus Q1 2024, with gross margin improving to 59.8% but operating loss widening to $16.8M (-39.9% of revenue) and net loss of $15.7M (diluted loss per share…
10-Q · October 30, 2024
Amarin reported Q3 net revenue of $42.298M, a sharp decline from $66.056M in the year‑ago quarter, driving a lower gross margin (38.5%) and a wider quarterly net loss of $25.134M (EPS -$0.06). Liquidity remains strong…
10-Q · July 31, 2024
Amarin reported Q2 total revenue of $67.49M (down from $80.17M in Q2 2023) and GAAP net income of $1.522M (basic/diluted EPS $0.00) versus a $17.56M loss in Q2 2023. Gross margin expanded to 63.4% (from 53.2% in Q2…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.